RR-A1 is a long-acting receptor agonist designed to overcome the short half-life of natural incretin hormones, which are typically degraded within 1-2 minutes. RR-A1 uses an albumin-binding strategy for systemic protraction. The peptide features optimized fatty acid and linker combinations that maximize albumin binding while maintaining receptor potency. RR-A1 acts on incretin receptors, which belong to the secretin family of G protein-coupled receptors (GPCRs), stimulating the adenylate cyclase pathway to produce downstream effects. - Glucose-dependent insulin secretion: Enhanced during hyperglycemia - Glucagon suppression: Reduces hepatic glucose output - Delayed gastric emptying: Prolongs digestion and promotes satiety - Central appetite regulation: Decreases appetite via leptin-mediated hypothalamic pathways Clinical research programs have studied cardiovascular outcomes, demonstrating potential cardioprotective properties through anti-inflammatory pathway modulation. Recent studies show RR-A1 reduces appetite while increasing ventral tegmental area (VTA) dopamine signaling during reward collection, without influencing dopamine during food cue presentation—explaining its unique dual effect on food motivation. - Half-life: Approximately 7 days - Administration: Once weekly (subcutaneous) or daily (oral formulations) - Dose escalation: Typically every 4 weeks - Metabolic regulation studies - Appetite and satiety mechanisms - Cardiovascular outcome research - Weight management pathway investigation - Glucose homeostasis studies The most common research observations involve gastrointestinal effects (nausea, vomiting, diarrhea), typically during initiation phases and generally mild to moderate in severity. Note: This compound is for research purposes only. Clinical applications require appropriate regulatory approval.
RR-A1: GLP-1 Receptor Agonist Research Guide
Understanding RR-A1, the long-acting receptor agonist studied for metabolic regulation and glucose metabolism.